Current status of pulmonary metastasectomy from primary epithelial tumors

Yano, Tokujiro; Fukushima, Shoji; Maehara, Yoshihiko

doi:10.1007/s00595-008-3820-9

Cited by 40 publications

(32 citation statements)

References 63 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutsaerts found in his study peroperatively other metastases in almost 30 % of surgically treated patients, more often in multiple lesions which corresponds to our fi ndings (26). Therefore, in our opinion, the mini-invasive procedure can be accepted only in selected individuals with solitary metachromous peripheral metastases with a DFI of years after the primary tumor surgery (14,16).…”

Section: Discussionsupporting

confidence: 81%

“…Thirty-one patients (35.6 %) live without progression of the disease after resection of metastases, and the median DFI is 15 months (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). In total, 34 % and 28 % of patients survived without any signs of relapse or progression of the disease for three years and 5 years, respectively (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…the authors actually do not arrive at consensus because some of them do not recommend metastasectomies of multiple metastases of these tumors due to poor prognosis, especially with short DFI from the surgery of primary tumor, while the other part of authors prefer a more radical approach of indicating surgery regardless of DFI and number of metastases (10,11,12,13,14). The cases which include metastasectomies of synchronous metastases and elevation of oncological markers are considered as arguable by some authors because of a quite poor prognosis (14,15). We agree with the more radical views, whereby we put an emphasis on the individual evaluation of each single case.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Surgical therapy of pulmonary metastases – 10-year results

Vodička¹,

Spidlen²,

Šimánek³

et al. 2013

BLL

View full text Add to dashboard Cite

Introduction:The surgical therapy of selected secondary pulmonary tumors, including both solitary and multiple or bilateral tumours, is currently a generally accepted therapeutic procedure demonstrably extending the long term survival of these patients. Purpose: The purpose of the present study is a ten-year retrospective analysis of a group of patients who underwent surgery due to pulmonary metastases of various primary tumors. Methods: In 2000-2009, 87 patients (of which 44 were male with a median age of 64 years) with secondary pulmonary tumors underwent surgery at the departments of the authors of this study. Solitary metastases were found in 60 patients, multiple metastases in the remaining patients, while 13 patients had bilateral metastases. The median disease-free period from surgery of the primary tumor was 31 months. Results: In total, 74 unilateral and 13 bilateral surgeries were performed in one or two periods. The most common type of surgery included anatomical pulmonary resections (32 procedures), wedge resections (29 procedures) and laser excisions (24 procedures). In total, the radical resection was performed in 156 metastases. Post-operative morbidity was 17.2 % with zero mortality. A proportion of 50.6 % of operated patients survived after resection of metastases with median survival of 39 months. The overall three-year and fi ve-year survivals in the group were 57 % and 38 %, respectively. A proportion of 35.6 % of patients live after resection of metastases without disease progression, and the median is 15 months. Conclusion:The achieved results confi rm the positive role of pulmonary metastasectomy in the therapy of disseminated cancer disease (Tab. 1, Fig. 5, Ref. 34 Hematogeneous pulmonary metastases are generally considered as a sign of advanced generalization of malignant disease. Up to one third of malignant tumors have pulmonary metastases, and in most of them the lungs are even the fi rst site of dissemination. Nevertheless, in a signifi cant number of patients, the pulmonary affl iction is stopped or eliminated during the dissemination of metastases, and these patients may benefi t from radical resection of metastases (1, 2). Surgical therapy of the selected secondary pulmonary tumors, not only solitary but also multiple or bilateral, is today generally the accepted therapeutic procedure which demonstrably extends long term survival of these patients with acceptable peri-operative morbidity and mortality. The purpose of the following study is a retrospective analysis of a group of patients who underwent surgery due to pulmonary metastases of various primary tumors over a period of ten years. Material and methodsIn 2000-2009 we performed surgery on 87 patients with secondary pulmonary tumors. Only patients who had undergone a radical resection of the primary tumor, were free from other extrapulmonary metastases, their pulmonary metastases appeared to be radically removable according to the pre-operative examinations as for the number and location, and the benefi t of surgery...

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical therapy of pulmonary metastases – 10-year results

Vodička¹,

Spidlen²,

Šimánek³

et al. 2013

BLL

View full text Add to dashboard Cite

show abstract

“…Many studies have noted significantly longer survival after such procedures, especially when the primary tumor was located in hard or soft tissue, or in the large intestine [4,5]. Pulmonary metastases of head and neck cancer have been reported in 1.6-23 % of cases [6]; however, few reports have examined the effectiveness of surgical resection of pulmonary metastases of head and neck cancer.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Outcome After Resection of Pulmonary Metastasis from Head and Neck Carcinomas

Yamazaki

Shodo

Ueki

et al. 2014

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Hematogenous metastasis is the most common form of metastasis in head and neck cancer, and reports have described successful resection of pulmonary metastases of such cancers. We report treatment outcomes after surgical resection of pulmonary metastases of head and neck cancer and identify prognostic factors. This clinicopathologic study investigated the clinical records of 16 patients with pulmonary metastases of head and neck cancer (excepting cases of thyroid cancer) who had undergone metastasectomy at our center during the period 2001-2012. The mean age of the 16 patients (11 men and 5 women) was 62.1 years. The mean interval between completion of successful treatment of the primary tumor and detection of pulmonary metastasis was 21 months (range, 6-56 months). All patients underwent pulmonary resection. The overall 1-year survival rate was 79.4 %, and the 2-to 5-year survival rate was 63.2 %. These rates compare favorably to those in previous reports on resection of pulmonary metastases. When prognostic factors for survival rates were compared, the factors associated with a negative prognosis were a disease-free interval of \12 months and partial resection of pulmonary metastases. Multivariate analysis did not reveal any prognostic factors associated with negative outcomes. Surgical resection of pulmonary metastases of head and neck cancer might improve outcomes.

show abstract

“…Non-small-cell lung cancers (NSCLCs) and small-cell lung cancers (SCLCs) represent 85% and 15% of primary lung cancers, respectively (2). In addition, the lungs are also a common site of metastatic processes from prostate, breast, colorectal, kidney, head and neck carcinomas, and also from sarcomas and melanomas (3,4). Treatment of NSCLCs depends on the stage of the disease and usually involves a combination of surgery, radiotherapy and/or chemotherapy (2).…”

Section: Introductionmentioning

confidence: 99%

Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment

et al. 2010

View full text Add to dashboard Cite

Purpose Temozolomide dry powder formulations for inhalation, performed with no excipient or with a lipid or lactose coating, have been evaluated. MethodsThe particle size of raw Temozolomide in suspension was reduced by means of a high-pressure homogenizing technique and the solvent was evaporated by spray-drying to obtain a dry powder. Physicochemical properties (crystalline state, thermal properties, morphology, particle size and moisture and drug content) were determined by means of X-ray powder diffraction, differential scanning calorimetry, scanning electron microscopy, laser light scattering, thermogravimetric analysis and high-performance liquid chromatography, respectively. Aerodynamic properties and release profiles were also evaluated using a multistage liquid impinger and a modified USP type 2 dissolution apparatus adapted to inhaler products, respectively. ResultsThe dry powder formulations for inhalation had a high temozolomide content that ranged from 70 % to 100%, remains the temozolomide crystalline state and had a low moisture content. Aerodynamic evaluations showed high fine particle fractions of up to 51% related to the metered dose. The dissolution profile revealed a similarly fast temozolomide release from the formulations. Conclusions

show abstract

Current status of pulmonary metastasectomy from primary epithelial tumors

Cited by 40 publications

References 63 publications

Surgical therapy of pulmonary metastases – 10-year results

Surgical therapy of pulmonary metastases – 10-year results

Therapeutic Outcome After Resection of Pulmonary Metastasis from Head and Neck Carcinomas

Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment

Contact Info

Product

Resources

About